MDN #024: Week of 2–8 November 2026

16 November 2026 - MDN - Medical Device News Archive

MDN #024: Week of 2–8 November 2026

The week of 2–8 November 2026 brought several relevant regulatory updates in the medical device and in vitro diagnostic (IVD) sectors.

This edition covers new MDCG guidance on clinical evidence for orphan IVDs, Team-NB’s proposals for improving the Clinical Evaluation Consultation Procedure, and an FDA discussion paper on autonomous and remotely operated medical robotics. It also includes recent developments in cybersecurity and health software standards, together with Health Canada’s updated list of recognized standards for medical devices.

In this issue

  1. MDCG publishes guidance on clinical evidence for orphan IVDs
  2. Team-NB publishes position paper on expert panels under Article 54 MDR
  3. FDA releases discussion paper on autonomous and remotely operated medical robotics
  4. Standards Watch — Cybersecurity and health software
  5. Health Canada updates recognized standards for medical devices

MDCG Publishes Guidance on Clinical Evidence for Orphan IVDs

On 3 November 2026, the European Commission published MDCG 2026-6 — Clinical evidence for orphan in vitro diagnostic medical devices.

This guidance sets out criteria for identifying orphan IVDs, including devices specifically intended to test for a disease, condition or circumstance affecting no more than 12,000 individuals in the European Union per year, where available alternatives are insufficient or the device is expected to provide a clinical benefit compared with existing options.

The epidemiological threshold concerns the affected population rather than the number of tests performed annually.

The document addresses the generation and assessment of clinical evidence for IVDs intended for small patient populations, where access to clinical specimens and performance data may be limited.

Limitations in pre-market clinical performance data may be acceptable where sufficient evidence supports the device’s safety, performance and expected clinical benefit. Any remaining limitations should be addressed through appropriate post-market surveillance (PMS) and post-market performance follow-up (PMPF) activities.

The guidance also describes notified body responsibilities and the involvement of expert panels in assessing orphan IVD status and clinical evidence.

Its clinical evidence principles are also relevant to orphan IVDs manufactured and used within health institutions under Article 5(5) of the IVDR.

The document provides manufacturers, notified bodies and health institutions with more specific guidance for planning and evaluating clinical evidence for orphan IVDs, without removing the applicable requirements of the IVDR.

Read the dedicated insight: Orphan medical devices: what they are and what MDCG guidance says under the MDR and IVDR

Source: Medical Device Coordination Group (MDCG)
Reference: MDCG 2026-6 — Clinical evidence for orphan in vitro diagnostic medical devices, MDCG


Team-NB Publishes Position Paper on Expert Panels under Article 54 MDR

On 8 November 2026, Team-NB published a position paper concerning the role and experience of expert panels under Article 54 of the MDR, drawing on notified bodies’ experience with the Clinical Evaluation Consultation Procedure (CECP).

The document acknowledges the contribution of expert panels to the scientific scrutiny of high-risk medical devices while identifying challenges related to administrative burden, the predictability of clinical evidence expectations, certification timelines and transparency.

In the context of a future MDR revision, Team-NB proposes limiting the scope of the CECP to Class III implantable devices, excluding Class IIb active devices intended to administer or remove medicinal products from the procedure.

The paper also recommends clearer boundaries for expert panel reviews, stronger exchanges between panels and notified bodies, and MDR-specific training for panel members.

Further proposals concern greater transparency regarding scientific opinions and the justifications provided during conformity assessment and certification.

These recommendations express the position of the European association of medical device notified bodies. They do not modify the current requirements of the MDR and do not constitute guidance issued by EU regulatory authorities.

The publication contributes to discussions on possible changes to the scope and operation of the CECP as part of the broader MDR revision debate.

Source: Team-NB
Reference: The Role and Experience of Expert Panels under Article 54 MDR: Reflections on the Clinical Evaluation Consultation Procedure (CECP) and Opportunities for Improvement, Team-NB


FDA Releases Discussion Paper on Autonomous and Remotely Operated Medical Robotics

On 6 November 2026, FDA released the discussion paper Evaluating Benefit-Risk in Robotic Medical Devices with Autonomous or Remote Teleoperation Capabilities.

The document examines robotic medical devices incorporating varying degrees of autonomy or remote teleoperation.

Its scope extends beyond robotically assisted surgical systems to include diagnostic, therapeutic and rehabilitative applications.

FDA is seeking stakeholder feedback on terminology, potential benefits and risks associated with these technologies, and possible approaches to risk mitigation.

The Agency explicitly states that the discussion paper is neither draft nor final guidance. It does not propose or implement policy changes and does not establish new regulatory expectations for the evaluation of robotic medical devices.

The deadline for submitting feedback is 5 January 2027.

The publication provides manufacturers, healthcare professionals and other stakeholders with an opportunity to contribute to FDA’s early discussions on emerging medical robotics technologies. It does not introduce new regulatory submission requirements.

Watch the video on YouTube: Autonomous and Remotely Operated Medical Robots: What Is the FDA Exploring?

Source: FDA
Reference: Evaluating Benefit-Risk in Robotic Medical Devices with Autonomous or Remote Teleoperation Capabilities, FDA


Standards Watch — Cybersecurity and Health Software

The November 2026 ISO Update reports several standards developments from October 2026 relevant to cybersecurity, connected healthcare and AI-enabled technologies.

The selected developments include two published documents and a draft standard currently under development.

ISO/IEC 27090:2026, published on 14 October 2026, provides guidance on identifying and mitigating security threats specific to artificial intelligence systems throughout their lifecycle.

The standard addresses AI-related cybersecurity risks and supports consideration of threats affecting AI systems during their development, operation and maintenance.

ISO/TS 6268-3:2026, published on 9 October 2026, is a technical specification addressing cybersecurity controls for telehealth systems and services.

It focuses on cybersecurity measures relevant to telehealth environments and forms part of the broader ISO/TS 6268 series.

ISO/DIS 81001-1 is a draft revision concerning principles and concepts for the safety, effectiveness and security of health software and health IT systems.

The draft remains at the enquiry stage and does not replace the existing edition of ISO 81001-1.

These developments may inform cybersecurity and software lifecycle activities for connected and AI-enabled healthcare technologies.

However, it is important to distinguish between the two published documents and ISO/DIS 81001-1, which remains a draft.

The developments were reported in the November ISO Update but relate to standards activity from October 2026, rather than new publications during the reporting week of 2–8 November.

Source: ISO / IEC
References: November ISO Update; ISO/IEC 27090:2026; ISO/TS 6268-3:2026; ISO/DIS 81001-1, ISO


Health Canada Updates Recognized Standards for Medical Devices

On 2 November 2026, Health Canada’s updated List of recognized standards for medical devices took effect.

The revision includes additions, removals and updates to the conditions and notes associated with recognized standards.

Among the additions are ISO 17665, concerning moist heat sterilization, and the ISO 18562 series, addressing the biocompatibility evaluation of breathing gas pathways in healthcare applications.

The updated list also includes standards concerning the safety of medical devices in magnetic resonance environments and IEC 80601-2-77, covering the basic safety and essential performance of robotically assisted surgical equipment.

Health Canada has also updated the recognition note associated with ISO 10993-1.

The note concerning Clause 6.5.11.2 of the 2025 edition indicates that devices falling within its scope may require additional testing beyond what is specified in that clause.

The publication updates the standards recognized within the Canadian medical device regulatory framework. It does not represent the publication of new ISO or IEC standards.

Manufacturers preparing medical device submissions in Canada should review the current recognized standards and any associated limitations when planning testing activities and declarations of conformity.

Source: Health Canada
Reference: List of recognized standards for medical devices, Health Canada


Share this article

If you find this article useful, you can share it with other professionals in the field.


Subscribe to MDN

Subscribers receive each new issue by email every Monday, one week before it is published on the website.

One email per week. No spam. Privacy Policy.


Latest issues


MDN Archive and News Collection

Browse all published MDN issues in the MDN Archive or search individual news items in the News Collection.